Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
10.0
5.5
Journals
Pharmaceutics
Special Issues
Population Pharmacokinetics: Where Are We Now?
share announcement

Population Pharmacokinetics: Where Are We Now?

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Pharmacokinetics and Pharmacodynamics".

Deadline for manuscript submissions: 28 February 2026 | Viewed by 349

Special Issue Editors

Dr. Su-jin Rhee

E-Mail Website
Guest Editor
College of Pharmacy, Wonkwang University, Iksan 54538, Republic of Korea
Interests: clinical pharmacokinetics (PK) and pharmacodynamics (PD); population PK/PD modeling and simulation; physiologically-based pharmacokinetic (PBPK) modeling and simulation; individualized pharmacotherapy; early phase clinical trial
Dr. Eunsol Yang

E-Mail Website
Guest Editor
Department of Bioengineering and Therapeutic Sciences, University of California, San Fransisco, CA, USA
Interests: pharmacometrics; clinical pharmacology; PK/PD modeling; translational modeling; model-informed dose optimization

Special Issue Information

Dear Colleagues,

We are pleased to invite you to contribute to our upcoming Special Issue, “Population Pharmacokinetics: Where Are We Now?”.

Population pharmacokinetics has become increasingly integrated across drug development, regulatory decision-making, and patient care. Its role in addressing knowledge gaps in both preclinical and clinical settings and thereby advancing global health continues to grow. Population pharmacokinetics provides robust quantitative foundations for dose selection and optimization, clinical trial design, and personalized therapy. This Special Issue aims to showcase recent methodological advances and innovative, impactful applications that reflect the current state and future direction of the field.

We welcome submissions aligned with, but not limited to, the following themes:

  1. Methodological advances

- Incorporation of machine learning into conventional population pharmacokinetic approaches.

- Innovative and automated approaches for covariate identification and model building.

  1. Model-informed drug development

- Translational pharmacokinetic/pharmacodynamic modeling to efficiently bridge preclinical findings to optimal human dose selection and clinical trial design.

- Population pharmacokinetics and exposure–response modeling to identify sources of variability and support rationale-driven development decisions.

  1. Model-informed advancements in current treatment strategies

- Population pharmacokinetics focused on special populations, such as pediatrics and pregnancy, to advance understanding and improve dosing strategies.

- Real-world data-based population pharmacokinetics in patient populations to enhance clinical practice.

We look forward to receiving your valuable contributions that advance the science and clinical applications of population pharmacokinetics.

Dr. Su-jin Rhee
Dr. Eunsol Yang
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pharmacometrics
  • population pharmacokinetics
  • pharmacokinetics/pharmacodynamics
  • machine learning
  • model-informed drug development
  • model-informed dose optimization
  • special populations
  • real-world data
  • personalized therapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

15 pages, 3734 KB  
Article
Toward Genotype-Informed Dosing of Voriconazole: Head-to-Head Simulations Across CYP2C19 Phenotypes Using Population Pharmacokinetic Models
by Yeobin Lee, Nai Lee, Su-jin Rhee and Yun Kim
Pharmaceutics 2025, 17(11), 1398; https://doi.org/10.3390/pharmaceutics17111398 (registering DOI) - 28 Oct 2025
Abstract
Background/Objective: Voriconazole exhibits nonlinear pharmacokinetics and wide interindividual variability driven by CYP2C19 phenotype and clinical covariates, necessitating early therapeutic drug monitoring (TDM). This study aimed to assess how the choice of population pharmacokinetic (PopPK) models influences genotype-stratified voriconazole exposure under a standardized adult [...] Read more.
Background/Objective: Voriconazole exhibits nonlinear pharmacokinetics and wide interindividual variability driven by CYP2C19 phenotype and clinical covariates, necessitating early therapeutic drug monitoring (TDM). This study aimed to assess how the choice of population pharmacokinetic (PopPK) models influences genotype-stratified voriconazole exposure under a standardized adult regimen, and to delineate model-specific implications for clinical prescribing. Methods: Five CYP2C19-informed PopPK models (Yun, Ling, Wang, Dolton, Friberg) were evaluated under one oral dosing scenario with an identical extensive metabolizers (EM)/intermediate metabolizer (IM)/poor metabolizers (PM) cohort; steady-state exposure metrics were compared across models, with sensitivity checks using model-specific cohorts. Results: Yun predicted the highest exposures with the steepest EM–IM–PM gradient, suggesting a need for caution against upper-tail exceedance when genotype effects are pronounced. Ling yielded intermediate exposures with a modest gradient, consistent with adult central tendencies, thus supporting its use for standard adult initial dosing. Wang primarily distinguished between EM and PM, proving useful for lower-bound checks where underexposure risk or limited genotype information is a concern. Friberg (and Dolton) demonstrated lower exposures with limited genotype separation, offering insights when persistent underexposure is suspected. Conclusions: These model-specific patterns indicate that PopPK model choice can influence initial dose-band selection and the timing of early TDM in routine adult care. Ling can serve as a baseline for standard adult initiation, whereas Yun is appropriate for safety-first scenarios when upper-tail risk from strong genotype effects is anticipated; Wang assists when IM data are lacking or when lower-bound checks are needed. Generalizability beyond standardized adult dosing (e.g., special populations) remains limited. Full article
(This article belongs to the Special Issue Population Pharmacokinetics: Where Are We Now?)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop